Navigation Links
Genentech/Roche/Chugai's Avastin Will Garner More Than 20 Percent of the Total Breast Cancer Drug Market in 2017
Date:10/21/2008

Significant Unmet Need Remains for Agents that are Effective in Treating Triple-Negative Beast Cancer, According to a New Report from Decision Resources

WALTHAM, Mass., Oct. 21 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that significant market penetration will drive Genentech/Roche/Chugai's Avastin to garner just over 20 percent of total sales in the breast cancer drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan in 2017.

The new Pharmacor report entitled Breast Cancer finds that, through 2017, the breast cancer drug market will be driven by sales of Avastin in the U.S. and Europe, its approval and launch in Japan, and its label extension to the adjuvant setting in 2013. Additionally, although Genentech/Roche/Chugai's Herceptin continues to dominate the human epidermal growth factor receptor-2 (HER2) positive breast cancer market segment, the drug is receiving strong competition from GlaxoSmithKline's Tykerb, which has received favorable physician opinion. However, Tykerb's premium price continues to limit its potential uptake, according to the report.

Market growth will also be driven by the entry of Pfizer's Sutent, currently in clinical trials, which is expected to be approved for the treatment of advanced breast cancer in 2010. Sutent's subsequent approval in the adjuvant setting between 2012 and 2017 will further drive its robust growth. Interviewed experts said they are strongly encouraged by Sutent's clinical trial data to date and express confidence in the drug's potential in breast cancer and are particularly hopeful of its potential in the treatment of triple-negative breast cancer. Triple-negative breast tumors--which account for approximately one-fifth of all breast cancers--are defined by their lack of expression of estrogen, progesterone and HER2 receptors.

"Lack of receptor expre
'/>"/>

SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Avastin Added to Chemo Helps Women With Advanced Breast Cancer
2. Avastin Added to Chemo Helps Women With Advanced Cancer
3. Off-Label Avastin Use for Wet Macular Degeneration
4. FDA OKs Avastin for Advanced Breast Cancer
5. In Combination With FOLFOX4, the Effect of Erbitux and Avastin On Survival Rates Will Drive Prescription Decisions in the Treatment of Stage III Colon Cancer
6. Despite Oncologists Willingness to Prescribe Avastin for Treatment of Breast Cancer, the FDA is Likely to Rule Against the Product on February 23
7. Many More Patients Can Now Benefit from Avastins Proven Survival Benefits
8. Taxol with avastin produces noteworthy results
9. FDA Panel Says No to Avastin for Advanced Breast Cancer
10. Rising Garners Top Honors on the Private Company Indexs Top Five Growth Companies List for Q1 2008
11. Study garners unique mating photos of wild gorillas

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...NFRANCISCO,Nov.25/PRNewswire/--TheBayAreaAirQualit...r Spare the Air Alert forThursday,No...logsoranyothersolidfuel,bothindoorsandoutdoors. ,...qualitytomorrow,"saidJackBroadbent,executiveoffice...spectthehealthoftheirneighborsandfellowcommunityme...
(Date:11/25/2009)...m survivors of testicular cancer who were treated ...side effects, including neurological side effects ...treated with chemotherapy, according to a new stud...the National Cancer Institute . , Marianne Brydy...niversity Hospital, in Bergen, Norway, and colleag...
(Date:11/25/2009)...uitous discovery that grew out of a collaboration ...ially offer hope to the nearly 10 million American... , Also known as hardening of the arteries, peri...latory problem in which narrowed arteries reduce b...d a red flag for vascular disease, heart attack an...
(Date:11/25/2009)...follow-up period was too short to draw definite co...Nov. 25 (HealthDay News) -- In diabetic patients w... no difference in outcomes at one year whether pat...tenting, British researchers report. , Bypass s...c patients with coronary artery disease. However, ...
(Date:11/25/2009)... Evaluation and treatment clinics t... Woodstock (Vocus) November 25, 2009 -- Centegra ...ccines and H1N1 vaccine shots at four Centegra Pri...shipment of vaccine has arrived. The clinics are a...d McHenry and will be open as follows: ,  ...
Breaking Medicine News(10 mins):Health News:Winter Spare the Air Alert in Effect for Thursday, November 26, 2009 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Stenting May Equal Bypass for Diabetic Heart Patients 2Health News:Stenting May Equal Bypass for Diabetic Heart Patients 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4
...al economic shutdown as some 2 million public ser...pute . 'It's going to be a total shutdown tomorrow... a massive strike involving marches in major citie... warned Tuesday. The comment came after ye...
... unconscious in his Kingston hotel room on 18 Marc...orld Cup . An initial pathologist's report had con... the Pakistan team was fingerprinted before return...ent expert opinions had concluded that the origina...
...turn the tables by declaring that some recent impo... standards and destroyed them . That was apparentl...the safety of a variety of products exported by Ch... in the north-eastern part of the country have bee...
...inated with carcinogens, for thirty years, a speci... and Prevention, reveals . The soldiers based...that contained around 40 times the safety limits o...of various forms of cancers and other illnesses am...
...g vaccines for children which are permissible unde...s here Tuesday ahead of an inaugural health confer...cials from the Organisation of the Islamic Confere...lu outbreaks and outbreaks of other infectious dis...
...re than leave you short-tempered: it can also stre...r disease and death, according to a study released...ural effects of long-term sleep loss have been wel...a School of Medicine adds to a growing body of evi...
Other Medicine News:Health News:South Africa Facing Major Economic Shutdown as Health Workers are Sacked En Masse 2Health News:No Foul Play, Woolmer Died of Naural Causes, Say Jamaican Police 2Health News:China Admits Fake Blood Protein Used in Drips 2Health News:Child Vaccines a Key Issue for OIC Forum in Malaysia 2Health News:Insufficient Sleep Increases Risk of Cardiovascular Disease: Study 2
(Date:11/25/2009)...AND,Colo.,Nov.25/PRNewswire-FirstCall/--HeskaCorpo...ddiagnosticandspecialtyproductstotheveterinaryindu...orporationforthesupplyofbloodgasproductsandaffilia... http://www.newscom.com/cgi-bin/prnh/20000622/HESK...innovatinginthefieldofadvancedpoint-of-carediagnos...
(Date:11/25/2009)...,Pa.,Nov.25/PRNewswire/--BioTrendsResearchGroup,In... report,thefirstinamulti-phasesyndicatedmarketres...ch,sStelara,fromproductlaunchthroughthefirstsixmon...itativeinformationfrom75uniqueDermatologistsandqua...strialanduseofStelara,obstaclestouse,typicalpatien...
(Date:11/25/2009)...NGRIDGE,N.J.,Nov.25/PRNewswire/--RegadoBiosciences...hromboticaptamerswithactivecontrolagents,announced...gatthePiperJaffray21stAnnualHealthCareConferenceat...ntationwillbegivenat1:10pm(EST)onTuesday,December1...emphasisontheleaddevelopmentprogram,theanticoagula...
Breaking Medicine Technology:Heska Announces Supply Agreement With Roche Diagnostics 2Heska Announces Supply Agreement With Roche Diagnostics 3Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009 2Imagenetix Inc Announces Interview With Bloomberg Radio 13589 1Imagenetix Inc Announces Interview With Bloomberg Radio 13589 2D Pharm Raises NIS 85 Million in Rights Offering and Initial Public Offering 28IPO 29 on the Tel Aviv Stock Exchange 28TASE 29 4857 1D Pharm Raises NIS 85 Million in Rights Offering and Initial Public Offering 28IPO 29 on the Tel Aviv Stock Exchange 28TASE 29 4857 2D Pharm Raises NIS 85 Million in Rights Offering and Initial Public Offering 28IPO 29 on the Tel Aviv Stock Exchange 28TASE 29 4857 3Genetic Discovery May Improve Hepatitis C Treatment 54618 1Genetic Discovery May Improve Hepatitis C Treatment 54618 2
...ehensive overview of clinical trials, ...AGO, Aug. 13 Aon eSolutions, the client,technolog...ding provider of,global risk and insurance solutio... Trials module as part of RiskConsole, the market-...system (RMIS)., (Logo: http://www.newscom.com/cg...
... could provide therapeutic benefit in c...ARLSBAD, Calif., Aug. 13 Isis,Pharmaceuticals, In...ed a,Phase 1 study of ISIS 353512, an antisense dr...ein (CRP). CRP levels are frequently elevated,in p...ovascular disease,Crohn,s disease, rheumatoid arth...
Other Medicine Technology:Aon eSolutions Launches Clinical Trials Module 2Aon eSolutions Launches Clinical Trials Module 3Aon eSolutions Launches Clinical Trials Module 4Isis Initiates Clinical Trial of CRP Drug 2Isis Initiates Clinical Trial of CRP Drug 3
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
Medicine Products: